StreetAlpha.app
Home › Stocks › DNTH

Dianthus Therapeutics, Inc. (DNTH)

Healthcare
$84.55
▼ −0.33%
LAST CLOSE · NOV 20

Dianthus Therapeutics develops experimental drugs for severe autoimmune diseases, led by the antibody claseprubart. It last closed at $84.55 on Nov 20, down 0.33% on the day. The next earnings report for DNTH is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, DNTH reported EPS of -$0.81. Over its last 8 reports the stock moved an average of 4.8% the session after earnings. Over the last 12 months DNTH insiders bought $0 of stock on the open market and sold $75.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is DNTH in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DNTH.

Key Stats

Last 12 months
Results
Net income
−$202.1M
EPS (diluted)
−$4.08
Valuation
Market cap
$4.8B
56.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$55.7M
At Sep 30
Shareholder equity
$1.2B
Shares outstanding
56.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $2.8M$2.8MFY2023FY2024: $6.2M$6.2MFY2024FY2025: $2.0M$2.0MFY2025

From DNTH's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.81
Quarter ended Sep 2026
Year ago EPS
-$0.97
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.82Dec '24Mar 2025: -$0.82Mar '25Jun 2025: -$0.88Jun '25Sep 2025: -$0.97Sep '25Dec 2025: -$1.52Dec '25Mar 2026: -$0.85Mar '26Jun 2026: -$0.90Jun '26Sep 2026: -$0.81Sep '26Latest -$0.81
Revenue by quarter
Dec 2024: $1.3MDec '24Mar 2025: $1.2MMar '25Jun 2025: $193,000Jun '25Sep 2025: $396,000Sep '25Dec 2025: $284,000Dec '25Latest $284,000
How DNTH moved after its last 8 reports
Average move the session after a report ±4.8%
Nov 4, 2026After the close−3.3%
Aug 4, 2026After the close+1.9%
May 5, 2026After the close+0.2%
Mar 9, 2026Time not announced+21.5%
Jan 12, 2026Time not announced+2.4%
Oct 16, 2025Time not announced−0.6%
Aug 7, 2025After the close−2.0%
May 12, 2025After the close−6.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on DNTHStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on DNTH
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on DNTH

Technical Analysis

DNTH · as of the Nov 20 close · updated each morning
Moving sideways

The stock is 1% below its 20 day and 2% below its 50 day average. It is 4% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 47). The nearest support is the Pivot at $84.25, and the nearest resistance the 20 day average at $85.42.

Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 5.4%/day
Key levels
$117.8852 week high+39.4%
$96.28100 day average+13.9%
$91.24Swing high (Oct 2)+7.9%
$87.81200 day average+3.9%
$86.3750 day average+2.2%
$85.97Pivot R1+1.7%
$85.4220 day average+1.0%
$84.55Last close
$84.25Pivot−0.4%
$83.84Swing low (Nov 12)−0.8%
$82.83Pivot S1−2.0%
$35.8452 week low−57.6%
Indicators
RSI (14)47.06Middle of its rangeNeutral
MACD0.45Above its signal lineBullish
Stochastic30.6Middle of its rangeNeutral
ADX (14)23.6Weak trend
Williams %R-68.7Oversold below −80, overbought above −20Neutral
CCI (20)-21.1Oversold below −100, overbought above 100Neutral
Rate of change−1.7%Change over 10 sessionsBearish
ATR (14)$4.54Typical daily range, 5.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DNTH

What happened before

See how DNTH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow DNTH usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How DNTH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for DNTHHow many large options trades hit DNTH, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

DNTH Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲151 buying vs 122 selling
  • ▲Held by funds +2.5 pts
  • ▲Funds holding +4
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding275271+1.5%
In funds' top 10810−20.0%
Held by funds119.8%117.3%+2.5 pts
New / increased42 / 10959 / 115−13.2%
Reduced / sold out84 / 3869 / 32+20.8%
Put/call ratio0.010.74−98.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DNTH institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DNTH Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$75.1M20 sales · 8 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $904K2026-03 sold $28.0M2026-04 sold $739K2026-05 sold $51K2026-06 sold $4.8M2026-07 sold $3.2M2026-08 sold $21.6M2026-09 sold $4.5M2026-11 sold $11.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 12Ryan SavitzEvp, CFO & CboSale plan124,042$90.52$11.2M
Sep 17Edward CarrChief Accounting OfficerSale plan20,000$101.38$2.0M
Sep 1Simrat RandhawaEVP, Head of R&DSale plan23,124$106.41$2.5M
Aug 19Simon ReadDirectorSale plan2,778$117.55$327K
Aug 10Simon ReadDirectorSale plan2,777$109.55$304K
Aug 10Adam M VenessSVP, General Counsel and Sec.Sale plan20,000$110.44$2.2M
Every insider buy and sale for DNTH over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See DNTH insider trades →

From SEC Form 4 filings by DNTH's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DNTH is in one of them and how their past DNTH trades turned out.

DNTH in the AI portfolios
Loading…

DNTH News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DNTH in an article yet. Here's the latest on the wider market.

DNTH in the news

About Dianthus Therapeutics

Dianthus Therapeutics is a biotechnology company based in New York that develops experimental drugs for people with severe autoimmune diseases. Its lead candidate, claseprubart, is an antibody that blocks the active form of the C1s protein, and it is designed to be injected under the skin at home. Its second candidate, DNTH212, is a fusion protein that targets two immune pathways involved in autoimmune disease. Both candidates are still in clinical trials and are not yet approved for sale.

Headquarters
New York, NY